News | May 24, 2025
Strides Pharma Q4 net profit rises 5x to Rs. 113 Cr
For the full year FY25, net profit soared 12x to Rs 345 crore
For the full year FY25, net profit soared 12x to Rs 345 crore
Approval brings AstraZeneca and Daiichi Sankyo’s Enhertu earlier in the treatment of HR-positive, HER2-low breast cancer and broadens the eligible patient population to those with HER2-ultralow disease
Q3 FY25 revenue up 24% to Rs 3,230 crore
Acquisition expands high-value medical platform
A 40 minute daily Yoga routine, incorporating select asanas and pranayama, along with standard lifestyle interventions, can reduce the risk of developing diabetes by approximately 40%
JB’s domestic business continued to out-perform the market with all our major brands posting strong growth
US Generics grew 5% to Rs. 467 Crores for the quarter
Revenue from Operations during Q2 FY25 was Rs. 3,077 crore as compared to Rs. 2,708 crore in Q2 FY24.
Showcases specialty and sustainable materials for healthcare at Medtec China 2024
Research & Development (R&D) investments for the quarter stood at Rs. 392.5 crore which is 6.3% of its revenues
Subscribe To Our Newsletter & Stay Updated
